CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Dr K Ravishankar discusses the need to educate patients about migraine so they understand the aims of treatment, and he stresses the importance of treating the disease, not just the attack.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
In the final video in the series, Dr K Ravishankar calls for more progress to be made in improving migraine care in India and presents a roadmap for achieving the changes that are needed.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
Dr K Ravishankar describes his approach to the treatment of episodic and chronic migraine, and how he addresses the challenge of patients who present with medication overuse headache.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
Turning to drugs used to prevent migraine attacks in India, Dr K Ravishankar discusses the range currently available to doctors and patients, and the impact of newer agents in chronic migraine.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
In the fifth video in the series, Dr K Ravishankar assesses the availability of drugs for the treatment of acute attacks of migraine in India, including the newer agents that doctors are hearing about.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
Dr K Ravishankar divides the reasons for under-diagnosis of migraine in India into patient- and physician-related issues, and explains that much depends on whether a patient can afford care.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
Dr K Ravishankar reviews the multiple barriers to migraine diagnosis that mean many people are unaware of the cause of their headaches and are unable to access the levels of specialist care that they need.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
Dr K Ravishankar describes the main migraine triggers to consider when assessing a patient in India as some are quite different from those reported in the medical literature based on studies in Europe and America.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
Migraine affects approximately 33 crore (330 million) people in India, and is responsible for a significant proportion of disability associated with neurological disorders, as Dr K Ravishankar explains.
This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of the educational activity.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
